Sign In
Buy NTLA
$13.02
-0.110 (-0.84%)
At Close: Jun 03, 2026
New Strong Sell Stocks for August 24th
12:59pm, Tuesday, 24'th Aug 2021
BGS, FTHM, NTLA, LEVL, and ELOX have been added to the Zacks Rank #5 (Strong Sell) List on August 24, 2021
Will Moderna's Interest Boost Gene Editing Stocks?
10:30am, Monday, 16'th Aug 2021
Our indicative theme of Gene Editing stocks has returned about 11% year-to-date, compared to the S&P 500 which is up by about 19% over the same period. However, the gains have overwhelmingly come from
How Are Genomics ETFs Responding to Q2 Earnings?
10:00am, Saturday, 14'th Aug 2021
Let's take a look at some big genomics earnings releases to see if these will impact ETFs exposed to the space.
Gene Editing Stocks: Why EDIT, NTLA, CRSP Stocks Are Climbing Today
03:34pm, Thursday, 05'th Aug 2021
Today, investors in gene editing stocks are seeing a lot of green as earnings were announced along with business updates from key players. The post Gene Editing Stocks: Why EDIT, NTLA, CRSP Stocks Are
Intellia Therapeutics, Inc. (NTLA) CEO John Leonard on Q2 2021 Results - Earnings Call Transcript
03:00pm, Thursday, 05'th Aug 2021
Intellia Therapeutics, Inc. (NTLA) CEO John Leonard on Q2 2021 Results - Earnings Call Transcript
Intellia Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress
07:30am, Thursday, 05'th Aug 2021
CAMBRIDGE, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/
The Top 3 Gene Editing Stocks to Own for the Next Decade
01:03pm, Monday, 12'th Jul 2021
Gene editing could revolutionize the way we treat diseases. Along the way, it could also create substantial opportunity for related stocks.
Intellia Therapeutics' Next Hurdles After Its Positive Clinical Results
07:01am, Sunday, 11'th Jul 2021
There are still some key unanswered questions for the biotech's promising gene-editing therapy.
Where Will ARK Genomic Revolution ETF Be in 5 Years?
06:12am, Saturday, 10'th Jul 2021
Cathie Wood's genomics ETF is making big bets on the "Genomic Age."
Is It Too Late to Buy Intellia Therapeutics?
05:19am, Saturday, 10'th Jul 2021
After skyrocketing 68% last week, will this stock keep running higher?
IDNA: Genetics Now Have A Lot Of Influence On Healthcare
03:12am, Saturday, 10'th Jul 2021
IDNA: Genetics Now Have A Lot Of Influence On Healthcare
A Comprehensive Guide to Genomic ETFs
05:17pm, Friday, 09'th Jul 2021
Genomic ETFs are expected to benefit from the favorable trends in the genomic editing space.
Looking to Play Intellia's Ground-Breaking Gene Therapy?
04:00pm, Tuesday, 06'th Jul 2021
Intellia Therapeutics (NTLA) CEO John Leonard believes that gene-editing therapy could come to market “very, very soon,” according to an interview on CNBC's Closing Bell, after news broke that CRI
3 Biotech Stocks Poised to Gain in the Second Half of 2021
09:46am, Tuesday, 06'th Jul 2021
Here we present three biotech companies, which outperformed the sector in the year so far and are likely to witness a winning run in the near term.
2 Reasons to Buy Intellia -- and 1 Big Reason Why I Won't
07:49am, Sunday, 04'th Jul 2021
After the clinical-stage biotech publicized promising data for its gene-editing treatment of a rare and fatal disease, its stock skyrocketed.
